已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

医学 彭布罗利珠单抗 卡铂 危险系数 吉西他滨 肿瘤科 化疗 内科学 杜瓦卢马布 癌症 顺铂 置信区间 免疫疗法
作者
Thomas B. Powles,Begoña P. Valderrama,Shilpa Gupta,Jens Bedke,Eiji Kikuchi,Jean H. Hoffman-Censits,Gopa Iyer,Christof Vulsteke,Se Hoon Park,Sang Joon Shin,Daniel Castellano,Giuseppe Fornarini,Jian‐Ri Li,Mahmut Gümüş,Nataliya Mar,Yohann Loriot,Aude Fléchon,Ignacio Durán,Alexandra Drakaki,Sujata Narayanan
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:390 (10): 875-888 被引量:1306
标识
DOI:10.1056/nejmoa2312117
摘要

BACKGROUND: No treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma. METHODS: We conducted a phase 3, global, open-label, randomized trial to compare the efficacy and safety of enfortumab vedotin and pembrolizumab with the efficacy and safety of platinum-based chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma. Patients were randomly assigned in a 1:1 ratio to receive 3-week cycles of enfortumab vedotin (at a dose of 1.25 mg per kilogram of body weight intravenously on days 1 and 8) and pembrolizumab (at a dose of 200 mg intravenously on day 1) (enfortumab vedotin-pembrolizumab group) or gemcitabine and either cisplatin or carboplatin (determined on the basis of eligibility to receive cisplatin) (chemotherapy group). The primary end points were progression-free survival as assessed by blinded independent central review and overall survival. RESULTS: A total of 886 patients underwent randomization: 442 to the enfortumab vedotin-pembrolizumab group and 444 to the chemotherapy group. As of August 8, 2023, the median duration of follow-up for survival was 17.2 months. Progression-free survival was longer in the enfortumab vedotin-pembrolizumab group than in the chemotherapy group (median, 12.5 months vs. 6.3 months; hazard ratio for disease progression or death, 0.45; 95% confidence interval [CI], 0.38 to 0.54; P<0.001), as was overall survival (median, 31.5 months vs. 16.1 months; hazard ratio for death, 0.47; 95% CI, 0.38 to 0.58; P<0.001). The median number of cycles was 12 (range, 1 to 46) in the enfortumab vedotin-pembrolizumab group and 6 (range, 1 to 6) in the chemotherapy group. Treatment-related adverse events of grade 3 or higher occurred in 55.9% of the patients in the enfortumab vedotin-pembrolizumab group and in 69.5% of those in the chemotherapy group. CONCLUSIONS: Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma, with a safety profile consistent with that in previous reports. (Funded by Astellas Pharma US and others; EV-302 ClinicalTrials.gov number, NCT04223856.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
epiphyllum完成签到 ,获得积分10
3秒前
kk完成签到 ,获得积分10
4秒前
4秒前
5秒前
5秒前
Maestro_S的应助被chy采纳,获得10
7秒前
8秒前
是追风的人啊完成签到 ,获得积分10
8秒前
lv完成签到 ,获得积分10
8秒前
9秒前
kakakaku完成签到 ,获得积分10
9秒前
10秒前
10秒前
pablo发布了新的文献求助10
10秒前
万能图书馆的应助被禾几采纳,获得10
10秒前
爆米花的应助被个性向卉采纳,获得10
10秒前
受伤筝完成签到 ,获得积分10
14秒前
15秒前
16秒前
16秒前
所所的应助被微山采纳,获得10
16秒前
李木子完成签到 ,获得积分10
17秒前
chen完成签到,获得积分10
17秒前
zhang123笛完成签到 ,获得积分10
18秒前
小小旭完成签到 ,获得积分10
18秒前
19秒前
Cakoibao的应助被jgz1215采纳,获得10
19秒前
20秒前
21秒前
panda发布了新的文献求助10
21秒前
结实初翠发布了新的文献求助10
21秒前
21秒前
23秒前
粗心的小鸽子完成签到,获得积分10
23秒前
23秒前
24秒前
zhangzhirui完成签到 ,获得积分10
24秒前
25秒前
25秒前
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184723
求助须知:如何正确求助?哪些是违规求助? 9573702
关于积分的说明 21832740
捐赠科研通 7782090
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558528
邀请新用户注册赠送积分活动 2481054